Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The results were shown in multiple posts on X. A clinical trial to prove the safety and efficacy of Elon Musk's brain implant is ongoing, with 12 people currently using the devices.
The research fund aims to track the health of Americans for decades, with the intent of housing the long-term health information of 70% to 90% of the population.
ChatGPT isn’t capable of unilaterally guiding care for patients with cirrhosis or the liver cancer it tends to spawn, hepatocellular carcinoma (HCC). However, the large-language AI tool can competently assist clinicians.
The interventional cardiologist is now working with vendor Supira Medical to help advance the company's next-generation percutaneous ventricular assist device.
A popular marketer of handheld ultrasound devices has won FDA approval for an AI-enabled B-line quantification tool for use with patients suspected of having compromised lung function.
Radiology AI vendor Bot Image may market its prostate software not only for diagnosing cancer when suspected but also for performing prostate screenings.